Fidaxomicin vs Vancomycin for C. diff Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two antibiotics, fidaxomicin and vancomycin, to determine which better treats C. difficile infections in people with inflammatory bowel disease (IBD). Researchers aim to identify which drug is safer and more effective at clearing the infection. Participants will be divided into two groups, each taking one of the antibiotics for 10 days. This trial may suit those diagnosed with IBD who plan to have an outpatient colonoscopy. As a Phase 4 trial, this research involves FDA-approved treatments and seeks to understand how these antibiotics can benefit more patients.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on chronic antibiotics, you may not be eligible to participate.
What is the safety track record for these treatments?
Research shows that both fidaxomicin and vancomycin are well-tolerated treatments for C. difficile infections, often called "C. diff." Fidaxomicin, a narrow-spectrum antibiotic, specifically targets C. diff bacteria. Studies have shown it effectively treats infections, with high success rates and few side effects.
Vancomycin, a broader antibiotic, is also approved for treating C. diff. It has been used for a long time and is known to be safe. Patients generally tolerate it well, with side effects being rare and usually mild.
The FDA has approved both medications for treating C. diff infections, indicating their safety for this use. This approval provides confidence in the safety of these treatments in the trial.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about fidaxomicin for treating C. diff infections because it offers a more targeted approach than the standard treatment options like vancomycin. Unlike vancomycin, which has a broad spectrum of action against many gram-positive bacteria, fidaxomicin specifically targets C. difficile, potentially leading to fewer side effects and less disruption of the normal gut flora. This narrow-spectrum approach helps preserve the beneficial bacteria in the gut, which may reduce the likelihood of recurrent infections — a significant issue with C. diff.
What is the effectiveness track record for fidaxomicin and vancomycin in treating C. diff infection?
This trial will compare Fidaxomicin and Vancomycin for treating C. difficile infections. Research has shown that fidaxomicin is more effective than vancomycin for this purpose. Studies found that patients using fidaxomicin had a lower chance of the infection returning, with a risk ratio of 0.52 compared to vancomycin. This indicates that fidaxomicin is less likely to see the infection return after treatment. Specifically, one study found that only 9.5% of patients treated with fidaxomicin experienced the main issue again, compared to 21.6% with vancomycin. Fidaxomicin also has a high success rate and results in fewer hospital readmissions. Both antibiotics are approved by the FDA for treating C. difficile, but fidaxomicin generally provides better long-term results.23567
Who Is on the Research Team?
Jessica Allegretti, MD, MPH
Principal Investigator
Brigham and Women's Hospital
Are You a Good Fit for This Trial?
This trial is for patients with Inflammatory Bowel Disease (IBD) who are also infected with C. difficile. Participants must meet certain health standards to be included, but specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either fidaxomicin or vancomycin for decolonization of C. difficile
Follow-up
Participants are monitored for safety, efficacy, and clinical outcomes after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fidaxomicin
- Vancomycin
Trial Overview
The study compares the safety and effectiveness of two antibiotics: Fidaxomicin (200 mg twice daily) versus Vancomycin (125 mg every 6 hours), both taken orally for 10 days, in IBD patients with C. difficile infection.
How Is the Trial Designed?
2
Treatment groups
Active Control
Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. The current approved dose is 125mg PO every 6 hours for 10 days. Appropriate dosing and tolerance of vancomycin is well defined in both healthy and hospitalized populations, as it is already approved and indicated by the FDA for use in treating C. difficile infection.
Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. The approved dose is 200mg PO twice daily for 10 days. Appropriate dosing and tolerance of fidaxomicin is well defined in both healthy and hospitalized populations, as it is already approved and indicated by the FDA for use in treating C. difficile infection.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Citations
The Clinical Effectiveness of Fidaxomicin Compared to ...
The primary outcome occurred in 8 (9.5%) in the fidaxomicin group compared to 111 (21.6%) in the vancomycin group. The adjusted multivariable ...
Articles Comparative effectiveness of different therapies for ...
Focusing solely on recurrent cases, we identified FMT as the best therapy. FMT is followed by fidaxomicin. Both therapies showed significantly better results ...
3.
cidrap.umn.edu
cidrap.umn.edu/antimicrobial-stewardship/fidaxomicin-underused-c-diff-infections-study-findsFidaxomicin underused for C diff infections, study finds
From the pre-period to the post-period, fidaxomicin use increased from 5.9% to 13.7%, while vancomycin used declined from 87.9% to 82.9% and ...
4.
journals.lww.com
journals.lww.com/md-journal/fulltext/2024/08090/efficacy_of_fidaxomicin_versus_vancomycin_in_the.81.aspxEfficacy of fidaxomicin versus vancomycin in the treatment...
Results showed that fidaxomicin was superior to vancomycin in terms of 40-day recurrence rate (RR = 0.52, 95% CI: 0.38–0.70, P < .01, Fig. 4A), ...
Fidaxomicin Use and Clinical Outcomes for Clostridium ...
In this real-world setting, fidaxomicin resulted in a high rate of clinical success, a low rate of recurrence, and a low readmission rate. Key Words: ...
Safety and Efficacy of Fidaxomicin and Vancomycin in ...
Conclusions: Compared with vancomycin, fidaxomicin was well tolerated and demonstrated significantly higher rates of GC in children and adolescents with CDI.
C. difficile 2021 Focused Update
The panel agrees that the overall balance of benefits and harms favors using fidaxomicin over vancomycin for an initial episode of CDI and that ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.